Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and CHOP in Gastric DLBCL
NCT00204659Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Mar 2003
- Primary completion
- Sep 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in primary gastric diffuse large B-cell lymphoma (PG-DLBCL), sponsored by University Hospital Tübingen. Primary endpoints: Complete Remission Rate and Progression-Free Survival at 5 years. Started Mar 2003; status: completed.
02
Drugs
rituximab
03
Conditions
primary gastric diffuse large B-cell lymphoma (PG-DLBCL)
Beyond the preview
Go deeper on NCT00204659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00204659.